Omda (OMDA) Panoramica del titolo
Omda AS fornisce soluzioni software per il settore sanitario in Norvegia, Svezia, Danimarca, Finlandia e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 1/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
OMDA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Omda AS
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | NOK 34.40 |
| Massimo di 52 settimane | NOK 56.60 |
| Minimo di 52 settimane | NOK 33.00 |
| Beta | 0.45 |
| Variazione di 1 mese | -17.11% |
| Variazione a 3 mesi | -11.57% |
| Variazione di 1 anno | -35.09% |
| Variazione a 3 anni | -28.18% |
| Variazione a 5 anni | -61.95% |
| Variazione dall'IPO | -58.55% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • May 10
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential
Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector. Analyst Commentary Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions.Aggiornamento della narrazione • Apr 20
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Support Upside Potential
Analysts have adjusted their Omda price target to NOK57.0, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions after recent research highlighted both reduced targets across several firms and continued confidence in Omda's growth runway and program momentum. Analyst Commentary Street research around Omda presents a mix of recalibrated price targets and continued confidence in the company’s ability to execute on its program pipeline.Recent updates
Aggiornamento della narrazione • May 10
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential
Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector. Analyst Commentary Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions.Aggiornamento della narrazione • Apr 20
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Support Upside Potential
Analysts have adjusted their Omda price target to NOK57.0, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions after recent research highlighted both reduced targets across several firms and continued confidence in Omda's growth runway and program momentum. Analyst Commentary Street research around Omda presents a mix of recalibrated price targets and continued confidence in the company’s ability to execute on its program pipeline.Aggiornamento della narrazione • Apr 06
OMDA: Q4 Outperformance And 2026 Guidance Conservatism Are Expected To Drive Upside
The updated analyst price target for Omda now reflects a more cautious tone seen across recent NOK-based targets, as analysts factor in refreshed models following Q4 results, revised guidance and ongoing debate around how conservative the medium-term outlook might be. Analyst Commentary Street research on Omda clusters around lowered price targets in the near term, but most firms are maintaining positive or neutral ratings, pointing to a mix of execution momentum and valuation questions.Aggiornamento della narrazione • Mar 23
OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Drive Upside
Analysts have trimmed the Omda fair value estimate from NOK 59 to NOK 57, reflecting updated price targets and modeling that factors in revised profit margin expectations, alongside supportive views on revenue growth and the broader program momentum flagged in recent research notes. Analyst Commentary Recent Street research on Omda points to a reset in expectations around valuation, while still highlighting execution on growth initiatives and Q4 performance.Aggiornamento della narrazione • Mar 08
OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Unlock Upside
Analysts have nudged our Omda price target slightly lower to NOK 59.0, reflecting modestly higher discount rate and P/E assumptions while still citing solid Q4 execution, program momentum and a generally supportive tone across recent research updates. Analyst Commentary Recent research paints a mixed but generally constructive picture around Omda, with most firms trimming price targets while still pointing to solid execution and program traction after Q4.Aggiornamento della narrazione • Feb 22
OMDA: Cardiometabolic Partnerships And Reduced Multiple Are Expected To Unlock Upside
Analysts have trimmed their Omda price targets by about NOK 3, reflecting slightly higher discount rate assumptions and a lower future P/E multiple, as they balance growth expectations with recent stock performance and client concentration risks. Analyst Commentary Recent Street research on Omda highlights a mix of optimism around the core business and caution around how that story translates into valuation and execution risk.Aggiornamento della narrazione • Feb 07
OMDA: Cardiometabolic Program Expansion And AI Platform Investment Will Drive Future Upside
Analysts have trimmed their average price targets on Omda by a few dollars, reflecting a slightly higher discount rate and a modestly higher assumed future P/E, while still pointing to a mix of growth opportunities in cardiometabolic programs and client concentration risks. Analyst Commentary Recent research on Omda reflects a mix of optimism around long term growth potential and caution around execution and concentration risks.Aggiornamento della narrazione • Jan 24
OMDA: GLP-1 Companion Expansion And AI Investment Will Drive Future Upside
Analysts have trimmed their blended price target for Omda by a few dollars to align with recent cuts and initiations around the $17 to $32 range, citing a combination of strong GLP-1 related momentum, partnership tailwinds, revenue growth potential, and concerns about client concentration and ownership complexity. Analyst Commentary Recent research on Omda reflects a mix of optimism around growth drivers and caution around concentration risks and ownership structure, which together help frame how analysts think about valuation and execution risk.Aggiornamento della narrazione • Jan 10
OMDA: Cardiometabolic Platform Expansion And AI Execution Will Support Future Upside Potential
Analysts have slightly adjusted their outlook on Omda, with a modest change in the implied fair value and Street price targets. This reflects updated views on discount rates, long term growth drivers, and mixed recent research that includes lower targets from Goldman Sachs and Wells Fargo, alongside more constructive targets from BMO Capital and Morgan Stanley.Aggiornamento della narrazione • Dec 22
OMDA: Expanded GLP-1 Programs And AI Offerings Will Drive Future Margin Upside
Analysts have raised their price target on Omda to $59.00, supported by expectations for sustained revenue growth above 20%, expanding margins, and accelerating adoption of its enhanced GLP-1 programs and AI driven offerings. Analyst Commentary Recent Street research reflects a predominantly constructive stance on Omda, with bullish analysts highlighting a combination of strong execution, favorable unit economics, and a long runway for growth as key drivers of upside to the newly raised price target.Aggiornamento della narrazione • Dec 08
OMDA: GLP 1 Program Expansion Will Drive Future Margin Upside
Analysts have raised their price target on Omda to $59.00 per share from a previously implied lower level, citing expectations for sustained 20% plus revenue growth, expanding margins, and accelerating GLP 1 related momentum as key drivers of upside. Analyst Commentary Recent Street commentary highlights a constructive backdrop for Omda, with bullish analysts pointing to a long runway for growth supported by a large, under-penetrated market, strong execution, and accelerating GLP 1 related initiatives.Aggiornamento della narrazione • Nov 24
OMDA: Expanding Market And AI Integration Will Drive Continued Growth Momentum
Analysts have significantly raised Omda's fair value estimate from $35 to $59. They cite strong revenue growth, improved profit margins, an expanding addressable market, and increased momentum in new product rollouts and profitability.Articolo di analisi • Oct 10
Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Aggiornamento della narrazione • Aug 23
M&A And Competition Will Shape Risk And Opportunity In Healthcare
Despite Omada’s stronger-than-expected growth in members and revenue, robust gross margin gains, and improving clinical partnerships, analysts have lowered the price target from NOK44.00 to NOK35.00 due to a more cautious broader outlook. Analyst Commentary Bullish analysts highlight Omada’s member and revenue growth significantly surpassing expectations, with first-quarter figures beating estimates by 6.7% and 11.5%, respectively.Articolo di analisi • May 23
Omda AS (OB:OMDA) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Omda AS ( OB:OMDA ) shares have been powering on, with a gain of 32% in the last thirty...Articolo di analisi • May 16
These 4 Measures Indicate That Omda (OB:OMDA) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Nuova narrazione • May 08
Restructuring, Acquisitions And AI Integration Will Secure Operational Efficiency
Restructuring completion and an enhanced acquisition strategy are expected to boost operational efficiency, revenue growth, and earnings.Articolo di analisi • Apr 08
Little Excitement Around Omda AS' (OB:OMDA) Revenues
Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now compared to the...Articolo di analisi • Jan 26
Omda (OB:OMDA) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Dec 21
The Market Doesn't Like What It Sees From Omda AS' (OB:OMDA) Revenues Yet
Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a buy right now compared to the...Articolo di analisi • Nov 13
Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Articolo di analisi • Jul 24
Returns At Omda (OB:OMDA) Are On The Way Up
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...Articolo di analisi • May 22
Omda's (OB:OMDA) Earnings Are Weaker Than They Seem
Despite posting some strong earnings, the market for Omda AS' ( OB:OMDA ) stock hasn't moved much. Our analysis...Articolo di analisi • Mar 24
Improved Revenues Required Before Omda AS (OB:OMDA) Stock's 28% Jump Looks Justified
Omda AS ( OB:OMDA ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month...Articolo di analisi • Jan 24
Fewer Investors Than Expected Jumping On Omda AS (OB:OMDA)
When close to half the companies operating in the Healthcare Services industry in Norway have price-to-sales ratios (or...Articolo di analisi • Nov 18
Omda's (OB:OMDA) Earnings May Just Be The Starting Point
Omda AS ( OB:OMDA ) recently posted some strong earnings, and the market responded positively. We have done some...Articolo di analisi • Jun 17
Are Investors Undervaluing CSAM Health Group AS (OB:CSAM) By 44%?
Key Insights The projected fair value for CSAM Health Group is kr81.03 based on 2 Stage Free Cash Flow to Equity CSAM...Rendimenti per gli azionisti
| OMDA | NO Healthcare Services | NO Mercato | |
|---|---|---|---|
| 7D | -9.5% | 3.6% | 3.2% |
| 1Y | -35.1% | -10.2% | 24.9% |
Ritorno vs Industria: OMDA ha avuto una performance inferiore rispetto al Norwegian Healthcare Services che ha registrato un rendimento -10.2 % nell'ultimo anno.
Rendimento vs Mercato: OMDA ha avuto una performance inferiore al mercato Norwegian che ha registrato un rendimento 24.9 % nell'ultimo anno.
Volatilità dei prezzi
| OMDA volatility | |
|---|---|
| OMDA Average Weekly Movement | 7.2% |
| Healthcare Services Industry Average Movement | 6.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in NO Market | 12.4% |
| 10% least volatile stocks in NO Market | 3.3% |
Prezzo delle azioni stabile: OMDA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Norwegian.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di OMDA è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1999 | 255 | Sverre Flatby | omda.com |
Omda AS fornisce soluzioni software per il settore sanitario in Norvegia, Svezia, Danimarca, Finlandia e a livello internazionale. Offre sistemi di gestione delle informazioni di laboratorio, tra cui Omda ProSang, un sistema di gestione del sangue, delle cellule e dei tessuti, e soluzioni di medicazione, tra cui Omda Cytodose, una soluzione per la gestione dei trattamenti oncologici. L'azienda fornisce anche soluzioni sanitarie connesse, tra cui Omda Cardio, uno strumento di archiviazione ECG e diagnostica; Omda CIMA, un'applicazione mobile per l'imaging medico; Omda Media, una soluzione di imaging medico basata sul web; Omda Medimaker, una soluzione per la gestione e il flusso di lavoro delle immagini; Omda Picsara, una soluzione per la gestione delle immagini; Omda Arcidis, un sistema integrato di teleradiologia; Omda Helsemail, uno strumento per il trasferimento dei dati dei pazienti; Omda Plutus, una piattaforma per il monitoraggio degli audit e del flusso di lavoro; Omda S7, una piattaforma di comunicazione sicura per l'e-care e Omda XDS, una soluzione per l'archiviazione e la gestione dei dati dei pazienti.
Omda AS Riepilogo dei fondamenti
| OMDA statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | NOK 705.46m |
| Utili (TTM) | -NOK 35.92m |
| Ricavi(TTM) | NOK 493.60m |
1.4x
Rapporto P/S-19.6x
Rapporto P/EOMDA è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| OMDA Conto economico (TTM) | |
|---|---|
| Ricavi | NOK 493.60m |
| Costo del fatturato | NOK 258.75m |
| Profitto lordo | NOK 234.85m |
| Altre spese | NOK 270.77m |
| Utili | -NOK 35.92m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Aug 27, 2026
| Utile per azione (EPS) | -1.75 |
| Margine lordo | 47.58% |
| Margine di profitto netto | -7.28% |
| Rapporto debito/patrimonio netto | -2,394.2% |
Come si è comportato OMDA nel lungo periodo?
Vedi performance storica e confrontoDividendi
1.4%
Rendimento attuale del dividendo146%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/22 21:13 |
| Prezzo dell'azione a fine giornata | 2026/05/22 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Omda AS è coperta da 3 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Kristian Støle | Carnegie Investment Bank AB |
| Emilie Engen | DNB Carnegie |
| Eirik Rafdal | DNB Carnegie |